Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Poppson Jan 14, 2013 5:49pm
154 Views
Post# 20836833

RE: RE: RE: RE: RE: RE: US Analysts

RE: RE: RE: RE: RE: RE: US Analysts

JayB1

Great point re. the monthly timing of those mentioned. Especially with NY liers (I mean lawyers) with no one else's tragedy to feed on. All I can do is follow the theory that if you don't feed cockroaches, they'll go somewhere else. Buy while it's low and offer your stock up for sale at exhorbitant prices to squeeze the holy-$@*$!% out of the shorts when their brokers can't find anything else to fill the gap. I, myself have an open order to sell all my NEPT stock at $6.99/shr. I'll do the same with my APO stock. I look forward to the day that the shorts are squealling like pigs trying to find shares to cover. Regards, Popps

Bullboard Posts